GrayBug was founded as a spin-out of the Wilmer Eye Institute of the Johns Hopkins University School of Medicine. Now dba GrayBug Vision - and publicly traded since September 24, 2020 - the firm is developing a continuum of proprietary micro and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company's proprietary polymer-based delivery technologies allow customizable sustained release of all therapeutic classes, including small and large molecule drugs, including proteins, aptamers and other biologics, when delivered intraocularly. These controlled-release drug delivery systems can be formulated into drug-loaded nanoparticles, microparticles and biodegradable implants for intraocular injection. In mid-November 2022 it was announced that Graybug and the firm CalciMedica had entered into a Definitive Merger Agreement (DMA) - a merger of the two firms that effectively created a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedicaÂ’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases.
